Subscribe

|Videos|February 1, 2023

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

Author(s)Manali Kamdar, MD, Matthew Lunning, DO, FACP

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Episodes in this series

EP. 1 Overview of Large B-Cell Lymphoma (LBCL)

EP. 1 Overview of Large B-Cell Lymphoma (LBCL)

EP. 2 CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

EP. 2 CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

EP. 3 Treatment Strategies for Patients with R/R LBCL

EP. 3 Treatment Strategies for Patients with R/R LBCL

EP. 4 CAR T-Cell Therapy as Second-Line Treatment in LBCL

EP. 4 CAR T-Cell Therapy as Second-Line Treatment in LBCL

EP. 5 Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

EP. 5 Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

EP. 6 Additional Key Data Updates from ASH 2022 on Treatment of LBCL

EP. 6 Additional Key Data Updates from ASH 2022 on Treatment of LBCL

EP. 7 Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

EP. 7 Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

EP. 8 Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

EP. 8 Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Latest CME

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

June 29, 2026

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Gabriela Hobbs, MD; Rami Komrokji, MD; Douglas A. Tremblay, MD

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas$

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Lori A. Leslie, MD; Alex Mejia, MD

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

July 8, 2026

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

10th Annual Live Medical Crossfire®: Hematologic Malignancies

In-Person + Virtual Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11-12, 2026

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

3-Part Webinar Series

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

Kentucky Society of Clinical Oncology

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

$(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas$

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Lori A. Leslie, MD; Alex Mejia, MD

$(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York$

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Case-based Simulation

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Jae Park, MD

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

John O. Mascarenhas, MD; Marina Kremyanskaya, MD, PhD; Douglas A. Tremblay, MD

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

Naval Daver, MD

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Claire Roddie, MD, PhD; Elias Jabbour, MD; Hagop Kantarjian, MD